The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) is a huge mover today! About 616,566 shares traded hands. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 50.50% since April 8, 2016 and is downtrending. It has underperformed by 56.14% the S&P500.
The move comes after 5 months positive chart setup for the $184.17 million company. It was reported on Nov, 10 by Barchart.com. We have $15.49 PT which if reached, will make NASDAQ:OCUL worth $256.00 million more.
Ocular Therapeutix Inc (NASDAQ:OCUL) Ratings Coverage
Out of 3 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ocular Therapeutix has been the topic of 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The company was initiated on Thursday, August 13 by Morgan Stanley. JMP Securities initiated the stock with “Outperform” rating in Thursday, August 11 report. Nomura initiated the shares of OCUL in a report on Wednesday, August 5 with “Buy” rating. The rating was maintained by Morgan Stanley on Tuesday, June 7 with “Overweight”. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, October 23. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) has “Overweight” rating given on Thursday, April 28 by Morgan Stanley. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) has “Overweight” rating given on Thursday, February 18 by Morgan Stanley.
According to Zacks Investment Research, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.”
Another recent and important Ocular Therapeutix Inc (NASDAQ:OCUL) news was published by Investorplace.com which published an article titled: “Why CSX Corporation (CSX), Ocular Therapeutix Inc (OCUL), and Ulta Salon …” on October 13, 2016.
OCUL Company Profile
Ocular Therapeutix, Inc., incorporated on September 12, 2006, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company’s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.